NJ Bio is pleased to announce that Dr. Jagath Reddy Junutula and Dr Zhihua Sui two well-known and esteemed industry experts in oncology drug discovery (including ADCs) and medicinal chemistry/drug discovery, respectively, have joined NJ Bio’s Scientific Advisory Board (SAB).
Zhihua is Vice President, Head of Chemistry & Head of Strategic Outsourcing, at Agios Pharmaceuticals in Cambridge, MA. For past 30 years, he has been an experienced drug hunter and a leader in drug discovery in both big pharma and biotech. Zhihua has extensive experience in drug discovery platforms such as SBDD, FBDD and mechanism-based designs and protein degradation. Jagath is the Senior Vice President, Research & Development, at ModMab Therapeutics, Inc. He has over 15 years of experience in oncology drug discovery and more than 25 years of experience in the life science research as a biochemist/molecular cell biologist. Jagath developed a novel THIOMAB technology platform to obtain engineered Antibody Drug Conjugates with defined number of drugs to improve therapeutic utility. His specialties include Target Discovery in Oncology, Antibody Discovery and Development, ADCs and Bi-specific antibodies.
